From DCAT Value Chain Insights (VCI)
The Swiss Agency for Therapeutic Products (Swissmedic), the national drug regulatory agency for Switzerland, reports that counterfeit packs of the preparation of Gilead Sciences' hepatitis C drug, Harvoni (ledipasvir/sofosbuvir), have been discovered in Israel. The plastic bottles, which originated in India, were imported via a Swiss trading company and contained white instead of genuine yellow film-coated tablets. Swissmedic is working with other European authorities to establish whether Harvoni packs with counterfeit contents have also been imported into other countries.
Harvoni was Gilead's top-selling drug in 2015 with sales of $13.9 billion
"Swissmedic advises against purchasing any medicine from unknown sources, and particularly against ordering via the Internet," said the agency. "There is no guarantee that medicines sold at very low prices from countries with no comparable medicines control system actually contain the declared active ingredient or the correct dosage of that active ingredient," said the agency in a statement.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription